Bibliography
- Chemogenomics in drug discovery. A medicinal chemistry perspective Kubinyi H, Müller G, editors Wiley-VCH, Weinheim, 2004
- Liao JJ-L. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem 2007;50(3):409-24
- Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006;2(7):358-64
- Okram B, Nagle A, Adrian FJ, et al. A general strategy for creating ‘‘inactive-conformation’’ Abl inhibitors. Chem Biol 2006;13:779-86
- Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science 2002;298(5600):1912-34
- Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-65
- Cohen P. Protein kinases – the major drug targets of the twenty-first century? Nature Rev Drug Discov 2002;1:309-15
- Folkman J. Angiogenesis: an organizing principle for drug discovery? Nature Rev Drug Discov 2007;6:273-86
- Litman P, Ohne O, Ben-Yaakov S, et al. A novel substrate mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway. Biochemistry 2007;46:4716-24
- Pargellis CA, Cole PA. Designing bisubstrate analog inhibitors for protein kinases. Pharmacol Ther 2002;93(2-3):145-57
- Parang K, Till JH, Ablooglu AJ, et al. Mechanism-based design of a protein kinase inhibitor. Nat Struct Biol 2001;8(1):37-41
- Lawrence DS, Niu J. Protein kinase inhibitors: The tyrosine-specific protein kinases. Pharmacol Ther 1998;77(2):81-114
- Zheng J, Knighton DR, Ten Eyck LF, et al. Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with magnesium-ATP and peptide inhibitor. Biochemistry 1993;32(9):2154-61
- Nolen B, Taylor S, Ghosh G. Regulation of protein kinases: controlling activity through activation segment conformation. Mol Cell 2004;15:661-75
- Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell 2002;109:275-282
- Johnson LN, Noble MEM, Owen DJ. Active and inactive protein kinases: structural basis for regulation. Cell 1996;85:149-58
- Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 2004;5:33-44
- Cole PA, Shen K, Qiao Y, et al. Protein tyrosine kinases Src and Csk: a tail's tale. Curr Opin Chem Biol 2003;7:580-5
- Hubbard SR, Wei L, Ellis L, et al. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 1994;372(6508):746-74
- Hubbard SR, Mohammadi M, Schlessinger J. Autoregulatory mechanisms in protein-tyrosine kinases. J Biol Chem 1998;273(20):11987-90
- Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004;18:2699-711
- Traxler PM, Furet P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol Ther 1999;82(2-3):195-206
- Traxler PM. Protein tyrosine kinase inhibitors in cancer treatment. Exp Opin Ther Pat 1997;7(6):571-88
- Ballard P, Bradbury RH, Harris CS, et al. Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket. Bioorg Med Chem Lett 2006;16:1633-7
- Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002;277(48):46265-72
- Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005;102(31):11011-6
- Yun CH, Boggon TJ, LI Y, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007;11:217-27
- Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2005;293(5531):876-80
- LA Rosee P, Corbin AS, Stoffregen EP, et al. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 2002;62(24):7149-53
- Wang Z, Canagarajah BJ, Boehm JC, et al. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998;6(9):1117-28
- Lee JC, Kassis S, Kumar S, et al. p38 Mitogen-activated protein kinase inhibitors – mechanisms and therapeutic potentials. Pharmacol Ther 1999;82(2-3):389-97
- Scapin G, Patel SB, Lisnock J, et al. The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity. Chem Biol 2003;10(8):705-12
- Fitzgerald CE, Patel SB, Becker JW, et al. Structural basis for p38α MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nat Struct Biol 2003;10(9):764-9
- Nar H, Messerschmidt A, Huber R, et al. Crystal structure analysis of oxidized pseudomonas aeruginosa azurin at pH 5.5 and pH 9.0. A pH-induced conformational transition involves a peptide bond flip. J Mol Biol 1991;221:765-72
- Angell RM, Angell TD, Bamborough P, et al. Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR. Bioorg Med Chem Lett 2008;18:324-8
- Angell RM, Bamborough P, Cleasby A, et al. Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode. Bioorg Med Chem Lett 2008;18:318-23
- Knapp S, Debreczeni J, Bullock A, et al. Crystal structure of the human Pim1 kinase domain. To be published; 2004
- Komander D, Kular GS, Schuttelkopf AW, et al. Interactions of LY333531 and other bisindolyl maleimide inhibitors with PDK1. Structure 2004;12(2):215-26
- Meijer L, Thunnissen AM, White AW, et al. Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol 2000;7(1):51-63
- Lougheed JC, Chen RH, Mak P, et al. Crystal structures of the phosphorylated and unphosphorylated kinase domains of the Cdc42-associated tyrosine kinase ACK1. J Biol Chem 2004;279(42):44039-45
- Sielecki TM, Johnson TL, LIU J, et al. Quinazolines as cyclin dependent kinase inhibitors. Bioorg Med Chem Lett 2001;11(9):1157-60
- Cheney IW, Yan S, Appleby T, et al. Identification and structure–activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. Bioorg Med Chem Lett 2007;17:1697-83
- Jacobs MD, Black J, Futer O, et al. Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002. J Biol Chem 2005;280(14):13728-34
- Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26(1):127-32
- Fabian MA, III WHB, Treiber DK, et al. A small molecule–kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23(3):329-36
- Sullivan JE, Holdgate GA, Campbell D, et al. Prevention of MKK6-dependent activation by binding to p38α MAP kinase. Biochemistry 2005;44(50):16475-90
- Vogtherr M, Saxena K, Hoelder S, et al. NMR characterization of kinase p38 dynamics in free and ligand-bound forms. Angew Chem Int Ed Engl 2006;45:993-7